Toxic shock syndrome consecutive to the presence of vaginal tampon for menstruation regressive after early haemodynamic optimization and activated protein C infusion;Choc toxique staphylococcique dans un contexte menstruel de port de tampons vaginaux d'évolution favorable après optimisation hémodynamique précoce et administration de protéine C activée

Annales Francaises d'Anesthesie et de Reanimation

Volumn 28, Issue 1, 2009, Pages 91-95

  Ellies, E ^a   Vallee F ^a   Mari, A ^a   Silva, S ^a   Bauriaud, R ^a   Fourcade, O ^a   Genestal, M ^a  

^a CHU PURPAN   (France)

Author keywords

Activated protein C; Clindamycin; Early goal therapy; Genetic polymorphisms; Menstrual toxic shock syndrome; Staphylococcus aureus

Indexed keywords

ACTIVATED PROTEIN C; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; DROTRECOGIN; HYDROCORTISONE; IMIPENEM; NORADRENALIN; OFLOXACIN; STAPHYLOCOCCUS TOXIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BLOOD OXYGEN TENSION; CASE REPORT; CONTINUOUS INFUSION; FEMALE; GENOTYPE; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; MENSTRUATION; MULTIPLE ORGAN FAILURE; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; TAMPON; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; CLINDAMYCIN; FEMALE; GENOTYPE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; MENSTRUAL HYGIENE PRODUCTS; MULTIPLE ORGAN FAILURE; OXYGEN; PROTEIN C; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 58749105458     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2008.10.020     Document Type: Article

References (20)

1. Jarraud S., Lina G., Vandenesch F., and Étienne J. Épidémiologie des infections toxémiques à Staphylocoque doré. Ann Fr Anesth Reanim 21 (2002) 370-374
2. Murray R.J. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 35 Suppl. 2 (2005) S25-S44
3. Dinges M.M., Orwin P.M., and Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13 (2000) 16-34
4. Hong-Geller E., and Gupta G. Therapeutic approaches to superantigens-based diseases: a review. J Mol Recognit 16 (2003) 91-101
5. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 (2004) 858-873
6. Rivers E., Nguyen B., Havstad S., Ressler J., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001 8) 1368-1377
7. Orban J.C., Deroche D., and Ichai C. Sepsis sévère : le contrôle glycémique. Ann Fr Anesth Reanim 25 (2006) 275-279
8. Mira J.P., and Chiche J.D. Immunité et polymorphismes génétiques. In: Sfar (Ed). Congrès national d'anesthésie et de réanimation. Conférences d'actualisation (2004), Elsevier, Paris 285-293
9. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
10. Camporota L., and Wyncoll D. Practical aspectsof treatment with drotrecogin alpha (activated). Crit Care 11 Suppl. 5 (2007) S7
11. De Backer D. Benefit-risk assessment of drotrecogin alpha (activated) in the treatment of sepsis. Drug Saf 30 (2007) 995-1010
12. Vincent J.L. Drotrecogin alpha (activated): the treatment for severe sepsis?. Expert Opin Biol Ther 7 (2007) 1763-1777
13. Parsonnet J., Hansmann M.A., Delaney M.L., Modern P.A., Dubois A.M., Wieland-Alter W., et al. Prevalence of toxic shock syndrome toxin-1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 43 (2005) 4628-4634
14. Watanabe E., Hirasawa H., Oda S., Matsuda K., Hatano M., and Tokuhisa T. Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor and interleukin-1-related gene polymorphisms. Crit Care Med 33 (2005) 89-97
15. De Backer D., Verdant C., Chierego M., Koch M., Gullo A., and Vincent J.L. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 34 (2006) 1918-1924
16. Levi M., and Van der Pol T. Recombinant human activated protein C: current insights into its of action. Crit Care 11 Suppl. 5 (2007) S3
17. Texereau J., Pene F., Chiche J.D., Rousseau C., and Mira J.P. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 32 (2004) S313-S319
18. Gibert C. Traitement des infections à Staphylocoques résistants à la méticilline : optimisation des traitements disponibles ou utilisation de nouvelles molécules. Réanimation 10 (2001) 329-335
19. Potel E. Association d'antibiotiques dans les infections à Staphylocoque doré : les arguments pour. Ann Fr Anesth Reanim 21 (2002) 406-409
20. Doment Y. Principes thérapeutiques des infections à Staphylocoques. Place et limites des molécules classiques. Ann Fr Anesth Reanim 21 (2002) 392-398